Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics (Nasdaq: XLO) granted a non-qualified stock option to purchase 5,700 shares to a new employee effective November 1, 2025, under its 2022 Inducement Stock Incentive Plan. The exercise price is $0.7967 per share, equal to the closing price on October 31, 2025. Each option has a 10-year term.
Vesting: 25% vests on the first anniversary of employment, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to continued service and plan/option agreement terms. The grant was made under Nasdaq Listing Rule 5635(c)(4).
Xilio Therapeutics (Nasdaq: XLO) ha assegnato un'opzione non qualificata per l'acquisto di 5.700 azioni a un nuovo dipendente con effetto dal 1 novembre 2025, ai sensi del suo 2022 Inducement Stock Incentive Plan. Il prezzo di esercizio è di $0,7967 per azione, pari al prezzo di chiusura del 31 ottobre 2025. Ogni opzione ha una durata di 10 anni. Vesting: 25% maturano al primo anniversario dell'assunzione, con il 75% restante che matura in 36 rate mensili uguali successivamente, soggetto a continuazione del servizio e ai termini del piano/accordo di opzione. L'assegnazione è stata effettuata ai sensi della Nasdaq Listing Rule 5635(c)(4).
Xilio Therapeutics (Nasdaq: XLO) otorgó una opción de compra de 5.700 acciones a un nuevo empleado con efecto a partir del 1 de noviembre de 2025, conforme a su Plan de Incentivo de Acciones por Inducción 2022. El precio de ejercicio es de $0,7967 por acción, igual al precio de cierre del 31 de octubre de 2025. Cada opción tiene un plazo de 10 años. Vesting: 25% vence en el primer aniversario de la contratación, y el 75% restante vence en 36 cuotas mensuales iguales a partir de entonces, sujeto a la continuación del servicio y a los términos del plan/acuerdo de opción. La concesión se realizó conforme a la Regla 5635(c)(4) de Nasdaq Listing.
Xilio Therapeutics (나스닥: XLO)은 2022년 인듀스먼트 스톡 인센티브 플랜에 따라 2025년 11월 1일부터 새로운 직원에게 5,700주의 비적격 주식매수선택권을 부여했습니다. 행사가격은 주당 $0.7967로, 이는 2025년 10월 31일 종가와 같습니다. 각 옵션의 만료 기한은 10년입니다. Vesting: 25%은 고용 1주년 시점에 vesting되고, 남은 75%은 이후 매월 36회 균등하게 vesting되며, 지속 근무 및 계획/옵션 계약 조건에 따라 다릅니다. 이 부여는 나스닥 상장 규칙 5635(c)(4)에 따라 이루어졌습니다.
Xilio Therapeutics (Nasdaq : XLO) a accordé une option d'achat d'actions non qualifiée pour acheter 5 700 actions à un nouvel employé à partir du 1er novembre 2025, en vertu de son Plan d'incitation sur actions d'induction 2022. Le prix d'exercice est de 0,7967 $ par action, égal au cours de clôture du 31 octobre 2025. Chaque option a une durée de 10 ans. Acquisition des droits: 25% se libère au premier anniversaire de l'emploi, les 75% restants se libèrent en 36 versements mensuels égaux par la suite, sous réserve de la poursuite du service et des termes du plan/accord d'option. L'octroi a été effectué conformément à la règle de cotation Nasdaq 5635(c)(4).
Xilio Therapeutics (Nasdaq: XLO) gewährt einem neuen Mitarbeiter eine nicht qualifizierte Aktienoption zum Kauf von 5.700 Aktien im Rahmen des 2022 Inducement Stock Incentive Plan, mit Wirkung ab dem 1. November 2025. Der Ausübungspreis beträgt 0,7967 $ pro Aktie, entsprechend dem Schlusskurs am 31. Oktober 2025. Jede Option hat eine Laufzeit von 10 Jahren. Vesting: 25% vestet am ersten Jahrestag der Anstellung, wobei die verbleibenden 75% in den folgenden 36 gleichen monatlichen Raten vestet, vorbehaltlich fortgesetzter Diensteleistung und der Bedingungen des Plans/Optionsvertrags. Die Gewährung erfolgte gemäß Nasdaq Listing Rule 5635(c)(4).
Xilio Therapeutics (ناسداك: XLO) منحت خيار أسهم غير مؤهل لشراء 5,700 سهم لموظف جديد اعتبارًا من 1 نوفمبر 2025، بموجب خطة تحفيز الأسهم بالاستقطاب 2022. سعر الإضراب هو 0.7967 دولار للسهم، وهو يساوي سعر الإغلاق في 31 أكتوبر 2025. لكل خيار مدة صلاحية 10 سنوات. الاستحقاق: 25% يتم الاستحقاق في الذكرى الأولى للالتحاق، بينما 75% المتبقية تستحق في 36 دفعة شهرية متساوية لاحقًا، رهناً باستمرار الخدمة وبنود الخطة/اتفاقية الخيار. المنحة أُتِمت وفقاً لقواعد إدراج ناسداك 5635(c)(4).
- None.
- None.
WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective November 1, 2025, the company granted a non-qualified stock option to purchase 5,700 shares of its common stock to one new employee under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.
The stock options have an exercise price of
The stock options are subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grant and were made as an inducement material to the individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated, or masked, immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is leveraging its proprietary platform to advance a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
Investor Contact
investors@xiliotx.com
Media Contact
Josie Butler, 1AB
josie@1abmedia.com
FAQ
What did Xilio Therapeutics (XLO) announce on November 3, 2025 about inducement grants?
What is the exercise price and term of the XLO inducement stock option granted Nov 1, 2025?
How does the XLO inducement option vest for the Nov 1, 2025 grant?
Under which plan and Nasdaq rule was Xilio's Nov 2025 option grant made?
Does the XLO option grant disclosed Nov 3, 2025 change company outstanding share counts?
Where can investors find the terms governing the Nov 1, 2025 XLO stock option grant?
